Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(1): 35–38. doi:10.14735/amgh202035.

Direct costs for the treatment of inflammatory bowel diseases

Zuzana Zelinková Orcid.org  1, Dušan Podmanický2,3, Barbora Kadlečková1

+ Affiliation

Summary

The direct cost of treating non-specific inflammatory bowel diseases (IBD) is an economically significant social burden. They include the cost of outpatient and hospital care, the cost of medicines and diagnostic procedures, and the share of these costs in the overall burden varies from country to country. It is therefore necessary to know the specific situation in the country in order to develop a cost reduction strategy. The present article reviews recent studies to assess the cost of IBD treatment in different countries and proposes possible measures to reduce these costs.

Keywords

inflammatory bowel disease, direct cost, health care

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (9): 1324–1338. doi: 10.1038/ajg.2015.233.
2. Maaser C, Sturm A, Vavricka SR et al. ECCO-ESGAR guideline for diagnostic assessment in IBD. Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2018; 13 (2): 144–164. doi: 10.1093/ecco-jcc/jjy113.
3. Jussila A, Virta LJ, Pukkala E et al. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis 2014; 8 (9): 1088–1096. doi: 10.1016/j.crohns.2014.02.015.
4. Alatab S, Sepanlou SG, Ikuta K et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5 (1): 17–30. doi: 10.1016/S2468-1253 (19) 30333-4.
5. Dearthealth. [online]. Available from: www.dearhealth.com.
6. Olén O, Askling J, Sachs MC et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014. Gut 2020; 69 (3): 453–461. doi: 10.1136/gutjnl-2018-317572.
7. Lichtenstein GR, Shahabi A, Seabury SA et al. Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol 2019. In press. doi: 10.1016/j.cgh.2019.07.022.
8. Pillai N, Dusheiko M, Maillard MH et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis 2019; 13 (6): 744–754. doi: 10.1093/ecco-jcc/jjz003.
9. Kuenzig ME, Benchimol EI, Lee L et al. The impact of inflammatory bowel disease in canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol 2019; 2 (Suppl 1): S17–S33. doi: 10.1093/jcag/gwy055.
10. Lo B, Vind I, Vester-Andersen MK et al. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a danish population-based inception cohort. J Crohns Colitis 2020; 14 (1): 53–63. doi: 10.1093/ecco-jcc/ jjz096.
11. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390 (10114): 2769–2778. doi: 10.1016/S0140-6736 (17) 32448-0.
12. Suchá V, Kadlečková B, Repáková B et al. Nedostatočná liečba tiopurínmi u pacientov s nešpecifickými zápalovými ochoreniami čreva odoslaných na anti TNF liečbu. Gastroent Hepatol 2016; 70 (4): 335–339. doi: 10.14735/amgh2016335.
13. de Boer NK, Peyrin-Biroulet L, Jharap B et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis 2018; 12 (5): 610–620. doi: 10.1093/ecco-jcc/jjx181.
14. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009; 58 (4): 492–500. doi: 10.1136/gut.2008.155812.
15. Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018; 3 (11): 790–802. doi: 10.1016/S2468-1253 (18) 30265-6.
16. de Groof EJ, Stevens TW, Eshuis EJ et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C trial. Gut 2019; 68 (10): 1774–1780. doi: 10.1136/ gutjnl-2018-317539.
17. Ponsioen CY, de Groof EJ, Eshuis EJ et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2017; 2 (11): 785–792. doi: 10.1016/S2468-1253 (17) 30248-0.
18. Kucharzik T, Wittig BM, Helwig U et al. Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol 2017; 15 (4): 535–542. doi: 10.1016/j.cgh.2016.10.040.
19. Taylor SA, Mallett S, Bhatnagar G et al. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn’s disease (METRIC): a multicentre trial. Lancet Gastroenterol Hepatol 2018; 3 (8): 548–558. doi: 10.1016/S2468-1253 (18)  30161-4.
20. Bryant RV, Friedman AB, Wright EK et al. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut 2018; 67 (5): 973–985. doi: 10.1136/gutjnl-2017-315655.
21. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017; 390 (10098): 959–968. doi: 10.1016/S0140-6736 (17) 31 327-2.

Credited self-teaching test